Article Text

Download PDFPDF

1123 Remission and Lupus Low Disease Activity State (LLDAS) are associated with a lower probability of flares in Systemic Lupus Erythematosus (SLE) patients. Data from the almenara lupus cohort
  1. Manuel F Ugarte-Gil1,2,
  2. Rocío V Gamboa-Cardenas1,2,
  3. Cristina Reategui-Sokolova1,3,
  4. Victor Pimentel-Quiroz1,2,
  5. Mariela Medina1,
  6. Claudia Elera-Fitzcarrald1,2,
  7. Zoila Rodriguez-Bellido1,4,
  8. Cesar Pastor-Asurza1,4,
  9. Risto Perich-Campos1,4 and
  10. Graciela S Alarcón5,6
  1. 1School of Medicine, Universidad Científica del Sur. Lima, Peru
  2. 2Rheumatology Department, Hospital Guillermo Almenara Irigoyen. EsSalud. Lima, Peru
  3. 3Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Universidad San Ignacio de Loyola, Lima, Peru
  4. 4School of Medicine, Universidad Nacional Mayor de San Marcos. Lima, Peru
  5. 5School of Medicine, The University of Alabama at Birmingham, Birmingham, AL USA
  6. 6School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Peru


Background Remission and LLDAS have been proposed as the treatment goal for SLE patients. Different investigators have reported that achieving these states prevent damage accrual; however, their independent impact on the occurrence of flares has been only scarcely evaluated. The aim of this study was to evaluate the independent impact of remission and LLDAS on flares.

Methods SLE patients from a single center cohort with at least two visits were included. Visits were performed every six months. Disease activity state was defined as three independent states: remission defined as a SLEDAI-2k (excluding serology) =0, physician global assessment (PGA)<0.5, prednisone daily dose≤5 mg/d and immunosuppressive drugs on maintenance dose (based on 2021 DORIS definition); LLDAS defined as a SLEDAI-2k≤4 with no activity in major organ systems, with no new features of lupus disease activity compared to the previous assessment, physician global assessment (PGA)≤1.0, prednisone daily dose≤7.5 mg/d; and the rest were defined as active. Flares were defined as an increase of at least four points in the SLEDAI-2k between two consecutive visits. Generalized estimating equations were performed, using as outcome the occurrence of a flare in the subsequent visit, and the activity state in the previous visit; multivariable models were adjusted for possible confounders [age, gender, socioeconomic status, educational level, disease duration, antimalarial use and SLICC/ACR damage index (SDI)]. All the confounders were measured in the same visit than the activity state.

Results Two hundred and eighty-one patients were included, they were followed-up for 2.7 (1.1) years. A total of 1346 visits were included, 730 (54.2%) of them were on remission, 190 (14.1%) were on LLDAS, and 426 (31.6%) were active. One hundred and one flares occurred during the follow-up among these 281 patients; 197 of them (70.1%) did not present flares, 67 (23.8%) presented one flare and 17 (6.0) presented two flares. Remission and LLDAS were associated with a lower probability of flares. Univariable and multivariable models are depicted in table 1.

Abstract 1123 Table 1

Factors associated with flares. Univariable and multivariable models

Conclusions Remission and LLDAS are independently associated with a lower probability of flares. These results reinforce the importance of these states as the goals of SLE treatment.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.